Bayer Backs Hot Flashes Drug For Blockbuster Status
As German Major Posts Decent Q3 Figures
Executive Summary
The menopause drug elinzanetant, which has just gone into Phase III, has joined Kerendia, Verquvo and Nubeqa as a candidate that Bayer believes has a peak sales potential of more than €1bn.
You may also be interested in...
Women’s Health Still Key to Bayer Despite Early Research Shift
The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.
Bullish Bayer Highlights Four Future Blockbusters
The German group has shone a light at the J.P. Morgan Healthcare Conference on its new launched drugs Nubeqa and Kerendia, plus its late-stage candidates asundexian and elinzanetant, as it prepares for life after patent expiries on Xarelto and Eylea.
Menopause Drug A Priority For Astellas
The Japanese group has used a priority review voucher for fezolinetant to move further ahead of Bayer’s elinzanetant as it seeks regulatory approval to bring a non-hormonal therapy for menopausal symptoms such as hot flashes and night sweats to market.